TAGStone Capital Inc. Has $3.50 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

TAGStone Capital Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,444 shares of the company’s stock after buying an additional 147 shares during the quarter. Johnson & Johnson accounts for about 3.3% of TAGStone Capital Inc.’s investment portfolio, making the stock its 6th largest position. TAGStone Capital Inc.’s holdings in Johnson & Johnson were worth $3,503,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Red Wave Investments LLC lifted its position in shares of Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock worth $530,000 after buying an additional 59 shares during the period. Argus Investors Counsel Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock worth $1,941,000 after buying an additional 61 shares during the period. Alta Capital Management LLC lifted its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after buying an additional 61 shares during the period. Paces Ferry Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after buying an additional 62 shares during the period. Finally, Mason & Associates Inc lifted its position in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after buying an additional 62 shares during the period. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Down 0.3 %

NYSE JNJ opened at $168.31 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The stock has a fifty day moving average of $176.07 and a 200-day moving average of $171.13. The stock has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on JNJ shares. Atlantic Securities dropped their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Sanford C. Bernstein dropped their price target on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Morgan Stanley dropped their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Bank of America dropped their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Finally, Credit Suisse Group started coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Insider Buying and Selling

In related news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock valued at $40,960,735 over the last three months. Company insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.